The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder Cancer

Daniel Petrylak, MD
Published Online:10:15 AM, Tue May 10, 2016

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.

The study evaluated atezolizumab given every three weeks at 1,200 mg. It also investigated the role of PD-L1 expression in the tumor immune cells, says Petrylak. It was determined that there was a better response rate in patients who were strong expressers of PD-L1 in the immune cells.

Previous trials have shown that there is no correlation between tumor cell expression of PD-L1 and outcome with anti PD-1 agents, explains Petrylak. However, when looking at just the immune cells, a positive relationship between PD-L1 expression and improved outcome with anti PD-1 agents was found.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.